BNTX vs. NVS: BioNTech vs. Novartis Stock Comparison

Company Profile

BioNTech (BNTX) and Novartis (NVS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while NVS is classified in Pharmaceuticals.

Both BioNTech (BNTX) and Novartis (NVS) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

BioNTech (BNTX) has an aggressive beta of 1.30, indicating higher sensitivity to broad-market moves, while Novartis (NVS) is defensive at 0.41 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Novartis (NVS) reports 24.33%, ranking against industry peers normally.

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Novartis (NVS) reports 17.49%, ranking against industry peers normally.

Both BioNTech (BNTX) at 30.28% and Novartis (NVS) at 34.27% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BioNTech (BNTX) at 4.32% and Novartis (NVS) at 9.57% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Novartis (NVS) reports EPS growth of 21.81%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Novartis (NVS) at 0.88 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVS.

BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Novartis (NVS) at 1.29 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

BioNTech (BNTX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a yield of 2.88%, ranking against industry peers normally.

BioNTech (BNTX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a payout of 90.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Novartis (NVS) trades at 31.02 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

On P/S ratio, both BioNTech (BNTX) at 8.96 and Novartis (NVS) at 5.35 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BioNTech (BNTX) at 1.09 looks cheap against book in the lower P/B ratio quartile, while Novartis (NVS) at 8.25 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics